Management of ANCA-associated vasculitis: Current trends and future prospects

References

• BoothADAlmondMKBurnsAOutcome of ANCA-associated renal vasculitis: A 5-year retrospective studyAm J Kidney Dis200341477678412666064
   PubMed Web of Science ®Google Scholar
• WaltonEWGiant-cell granuloma of the respiratory tract (Wegener’s granulomatosis)BMJ19582509126527013560836
   PubMed Web of Science ®Google Scholar
• JayneDRasmussenNAndrassyKA randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodiesN Engl J Med20033491364012840090
   PubMed Web of Science ®Google Scholar
• MattesonELGoldKNBlochDAHunderGGLong-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria CohortAm J Med199610121291348757351
   PubMed Web of Science ®Google Scholar
• WestmanKWBygrenPGOlssonHRanstamJWieslanderJRelapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvementJ Am Soc Nephrol1998958428529596082
   PubMed Web of Science ®Google Scholar
• HoffmanGSKerrGSLeavittRYWegener granulomatosis: An analysis of 158 patientsAnn Intern Med199211664884981739240
   PubMed Web of Science ®Google Scholar
• JennetteJCFalkRJAndrassyKNomenclature of systemic vasculitides. Proposal of an international consensus conferenceArthritis Rheum19943721871928129773
   PubMed Web of Science ®Google Scholar
• WattsRALaneSEBenthamGScottDGEpidemiology of systemic vasculitis: A ten-year study in the United KingdomArthritis Rheum200043241441910693883
   PubMed Web of Science ®Google Scholar
• European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIALClin Exp Immunol1995101Suppl 129
   PubMedGoogle Scholar
• HagenECDahaMRHermansJDiagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay StandardizationKidney Int19985337437539507222
   PubMed Web of Science ®Google Scholar
• MukhtyarCLeeRBrownDModification and validation of the Birmingham Vasculitis Activity Score (version 3)Ann Rheum Dis200968121827183219054820
   PubMed Web of Science ®Google Scholar
• ExleyARBaconPALuqmaniRADevelopment and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitidesArthritis Rheum19974023713809041949
   PubMed Web of Science ®Google Scholar
• MulderAHHeeringaPBrouwerELimburgPCKallenbergCGActivation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): A Fc gamma RII-dependent processClin Exp Immunol19949822702787955533
   PubMed Web of Science ®Google Scholar
• WilliamsJMBen-SmithAHewinsPActivation of the G(i) heterotrimeric G protein by ANCA IgG F(ab’)2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgGJ Am Soc Nephrol200314366166912595502
   PubMed Web of Science ®Google Scholar
• HarperLCockwellPAduDSavageCONeutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitisKidney Int20015951729173811318943
   PubMed Web of Science ®Google Scholar
• HattarKBickenbachACsernokEWegener’s granulomatosis: Antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activationJ Leukoc Biol2002716996100412050185
   PubMed Web of Science ®Google Scholar
• RadfordDJSavageCONashGBTreatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesionArthritis Rheum20004361337134510857792
   PubMedGoogle Scholar
• CockwellPBrooksCJAduDSavageCOInterleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritisKidney Int199955385286310027922
   PubMed Web of Science ®Google Scholar
• HarperLRenYSavillJAduDSavageCOAntineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophagesAm J Pathol2000157121122010880391
   PubMed Web of Science ®Google Scholar
• BansalPJTobinMCNeonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvementAnn Allergy Asthma Immunol200493439840115521377
   PubMed Web of Science ®Google Scholar
• XiaoHHeeringaPHuPAntineutrophil cytoplasmic auto-antibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in miceJ Clin Invest2002110795596312370273
   PubMed Web of Science ®Google Scholar
• XiaoHSchreiberAHeeringaPFalkRJJennetteJCAlternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodiesAm J Pathol20071701526417200182
   PubMed Web of Science ®Google Scholar
• XiaoHHeeringaPLiuZThe role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodiesAm J Pathol20051671394515972950
   PubMed Web of Science ®Google Scholar
• LittleMASmythCLYadavRAntineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivoBlood200510662050205815933057
   PubMed Web of Science ®Google Scholar
• PfisterHOllertMFrohlichLFAntineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivoBlood200410451411141815150076
   PubMed Web of Science ®Google Scholar
• PinchingAJReesAJPussellBALockwoodCMMitchisonRSPetersDKRelapses in Wegener’s granulomatosis: The role of infectionBMJ198028162448368387427471
   PubMedGoogle Scholar
• KainRExnerMBrandesRMolecular mimicry in pauci-immune focal necrotizing glomerulonephritisNat Med200814101088109618836458
   PubMed Web of Science ®Google Scholar
• PendergraftWF3rdPrestonGAShahRRAutoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3Nat Med2004101727914661018
   PubMed Web of Science ®Google Scholar
• StegemanCATervaertJWSluiterWJMansonWLde JongPEKallenbergCGAssociation of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosisAnn Intern Med1994120112178250451
   PubMed Web of Science ®Google Scholar
• StegemanCATervaertJWde JongPEKallenbergCGTrimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study GroupN Engl J Med1996335116208637536
   PubMed Web of Science ®Google Scholar
• CunninghamMAHuangXRDowlingJPTippingPGHoldsworthSRProminence of cell-mediated immunity effectors in “pauci-immune” glomerulonephritisJ Am Soc Nephrol199910349950610073600
   PubMed Web of Science ®Google Scholar
• LamprechtPGrossWLCurrent knowledge on cellular interactions in the WG-granulomaClin Exp Rheumatol2007251 Suppl 44S49S5117428367
   PubMed Web of Science ®Google Scholar
• GriffithMECoulthartAPuseyCDT cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitisClin Exp Immunol199610322532588565308
   PubMed Web of Science ®Google Scholar
• SchmittWHHagenECNeumannITreatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): An open study in 15 patientsKidney Int20046541440144815086487
   PubMed Web of Science ®Google Scholar
• NogueiraEHamourSSawantDSerum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitisNephrol Dial Transplant1252010 [Epub ahead of print].
   Web of Science ®Google Scholar
• Muller KoboldACKallenbergCGTervaertJWMonocyte activation in patients with Wegener’s granulomatosisAnn Rheum Dis199958423724510364903
   PubMed Web of Science ®Google Scholar
• MahrADNeogiTMerkelPAEpidemiology of Wegener’s granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinantsClin Exp Rheumatol2006242 Suppl 41S82S9116859601
   PubMed Web of Science ®Google Scholar
• CarrEJClatworthyMRLoweCEContrasting genetic association of IL2RA with SLE and ANCA-associated vasculitisBMC Med Genet2009102219265545
   PubMed Web of Science ®Google Scholar
• CarrEJNiedererHAWilliamsJConfirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitisBMC Med Genet20091012119951419
   PubMed Web of Science ®Google Scholar
• RarokAAStegemanCALimburgPCKallenbergCGNeutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitisJ Am Soc Nephrol20021392232223812191967
   PubMed Web of Science ®Google Scholar
• AlcortaDABarnesDADooleyMALeukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritisKidney Int200772785386417667990
   PubMed Web of Science ®Google Scholar
• JayneDUpdate on the European Vasculitis Study Group trialsCurr Opin Rheumatol2001131485511148715
   PubMed Web of Science ®Google Scholar
• FauciASHaynesBFKatzPWolffSMWegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 yearsAnn Intern Med198398176856336643
   PubMed Web of Science ®Google Scholar
• de GrootKHarperLJayneDRPulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trialAnn Intern Med20091501067068019451574
   PubMed Web of Science ®Google Scholar
• JayneDRGaskinGRasmussenNRandomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitisJ Am Soc Nephrol20071872180218817582159
   PubMed Web of Science ®Google Scholar
• de GrootKRasmussenNBaconPARandomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum20055282461246916052573
   PubMed Web of Science ®Google Scholar
• HuWLiuCXieHChenHLiuZLiLMycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvementNephrol Dial Transplant20082341307131218065810
   PubMed Web of Science ®Google Scholar
• HoganSLFalkRJChinHPredictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitisAnn Intern Med2005143962163116263884
   PubMed Web of Science ®Google Scholar
• Talar-WilliamsCHijaziYMWaltherMMCyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosisAnn Intern Med199612454774848602705
   PubMed Web of Science ®Google Scholar
• Reinhold-KellerEFinkCOHerlynKGrossWLde GrootKHigh rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexateArthritis Rheum200247332633212115164
   PubMedGoogle Scholar
• LangfordCATalar-WilliamsCBarronKSSnellerMCUse of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: Extended follow-up and rate of relapseAm J Med2003114646346912727579
   PubMed Web of Science ®Google Scholar
• PagnouxCMahrAHamidouMAAzathioprine or metho-trexate maintenance for ANCA-associated vasculitisN Engl J Med2008359262790280319109574
   PubMed Web of Science ®Google Scholar
• MayerADDmitrewskiJSquiffletJPMulticenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study GroupTransplantation19976434364439275110
   PubMed Web of Science ®Google Scholar
• HaubitzMKochKMBrunkhorstRCyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitisNephrol Dial Transplant1998138207420769719168
   PubMed Web of Science ®Google Scholar
• KawasakiSNakamuraHHondaETacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhageClin Rheumatol20072671211121416900300
   PubMed Web of Science ®Google Scholar
• TokudaMKurataNMizoguchiAEffect of low-dose cyclosporin A on systemic lupus erythematosus disease activityArthritis Rheum19943745515588147933
   PubMed Web of Science ®Google Scholar
• MangerKKaldenJRMangerBCyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical studyBr J Rheumatol19963576696758670602
   PubMedGoogle Scholar
• CaccavoDLaganaBMitterhoferAPLong-term treatment of systemic lupus erythematosus with cyclosporin AArthritis Rheum199740127359008597
   PubMed Web of Science ®Google Scholar
• MokCCTongKHToCHSiuYPAuTCTacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot studyKidney Int200568281381716014060
   PubMed Web of Science ®Google Scholar
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study GroupTransplantation1996617102910378623181
   PubMed Web of Science ®Google Scholar
• LangfordCATalar-WilliamsCSnellerMCMycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosisArthritis Rheum200451227828315077273
   PubMedGoogle Scholar
• HiemstraTHWalshMWSchmittWHJayneDRandomised controlled trial of mycophenolate mofetil versus azathioprine for maintenance therapy in ANCA-Associated vasculitis (IMPROVE). 1–4th Nov American Society of Nephrology 2009: SA-FC331A.
   Google Scholar
• GirardTMahrANoelLHAre antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener’s granulomatosis? A prospective studyRheumatology (Oxford)200140214715111257150
   PubMed Web of Science ®Google Scholar
• HanWKChoiHKRothRMMcCluskeyRTNilesJLSerial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitisKidney Int20036331079108512631091
   PubMed Web of Science ®Google Scholar
• TervaertJWHuitemaMGHeneRJPrevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titreLancet199033687177097111975893
   PubMed Web of Science ®Google Scholar
• MetzlerCMiehleNMangerKElevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosisRheumatology (Oxford)20074671087109117519271
   PubMed Web of Science ®Google Scholar
• BoothAHarperLHammadTProspective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitisJ Am Soc Nephrol200415371772114978174
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLValverdeVRTreatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance reportArthritis Rheum20034882122212712905464
   PubMed Web of Science ®Google Scholar
• Wegener’s Granulomatosis Etanercept Trial Research GroupEtanercept plus standard therapy for Wegener’s granulomatosisN Engl J Med2005352435136115673801
   PubMed Web of Science ®Google Scholar
• JonesRBFerraroAJChaudhryANA multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitisArthritis Rheum20096072156216819565480
   PubMed Web of Science ®Google Scholar
• CarsonKREvensAMRicheyEAProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood2009113204834484019264918
   PubMed Web of Science ®Google Scholar
• JonesRTervaertJWHauserTRandomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS. Proceedings of the 14th International Vasculitis and ANCA workshop. 6–9 Jun, 2009. Lund SwedenAPMIS2009117S127A22
   PubMedGoogle Scholar
• SpecksURituximab for ANCA-associated vasculitis (the RAVE-trial)Presented at: 14th International Vasculitis and ANCA workshop6–9 Jun 2009Lund, Sweden
   Google Scholar
• SmithKGJonesRBBurnsSMJayneDRLong-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatmentArthritis Rheum20065492970298216947528
   PubMed Web of Science ®Google Scholar
• BirckRWarnatzKLorenzHM15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacyJ Am Soc Nephrol200314244044712538745
   PubMed Web of Science ®Google Scholar
• LockwoodCMThiruSStewartSTreatment of refractory Wegener’s granulomatosis with humanized monoclonal antibodiesQJM199689129039129015484
   PubMed Web of Science ®Google Scholar
• WalshMChaudhryAJayneDLong-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)Ann Rheum Dis20086791322132718055469
   PubMed Web of Science ®Google Scholar
• MartinezVCohenPPagnouxCIntravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patientsArthritis Rheum200858130831718163506
   PubMedGoogle Scholar
• JayneDRLockwoodCMIntravenous immunoglobulin as sole therapy for systemic vasculitisBr J Rheumatol19963511115011538948304
   PubMedGoogle Scholar
• GenoveseMCKaineJLLowensteinMBOcrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging studyArthritis Rheum20085892652266118759293
   PubMed Web of Science ®Google Scholar
• CastilloJMilaniCMendez-AllwoodDOfatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disordersExpert Opin Investig Drugs2009184491500
   PubMed Web of Science ®Google Scholar
• GrossJAJohnstonJMudriSTACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune diseaseNature2000404678199599910801128
   PubMed Web of Science ®Google Scholar
• Trial watch: BLYS-targeted antibody shows promise in Phase III SLE trialNat Rev Drug Discov200989688
   Web of Science ®Google Scholar
• ScapiniPNardelliBNadaliGG-CSF-stimulated neutrophils are a prominent source of functional BLySJ Exp Med2003197329730212566413
   PubMed Web of Science ®Google Scholar
• PetriMStohlWChathamWAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis Rheum20085882453245918668552
   PubMed Web of Science ®Google Scholar
• KrumbholzMSpecksUWickMKalledSLJenneDMeinlEBAFF is elevated in serum of patients with Wegener’s granulomatosisJ Autoimmun200525429830216242914
   PubMed Web of Science ®Google Scholar
• HahneMKataokaTSchroterMAPRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growthJ Exp Med19981886118511909743536
   PubMed Web of Science ®Google Scholar
• NestorovIMunafoAPapasouliotisOVisichJPharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritisJ Clin Pharmacol200848440641718303125
   PubMed Web of Science ®Google Scholar
• HuugenDvan EschAXiaoHInhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in miceKidney Int200771764665417299525
   PubMed Web of Science ®Google Scholar
• RothenbergMEKlionADRoufosseFETreatment of patients with the hypereosinophilic syndrome with mepolizumabN Engl J Med2008358121215122818344568
   PubMed Web of Science ®Google Scholar
• KawashiriSYKawakamiAIwamotoNSwitching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologicsMod Rheumatol2010201404519802651
   PubMed Web of Science ®Google Scholar
• PaustHJTurnerJESteinmetzOMThe IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritisJ Am Soc Nephrol200920596997919339380
   PubMed Web of Science ®Google Scholar
• GanPYSteinmetzOMTanDSTh17 cells promote autoimmune anti-myeloperoxidase glomerulonephritisJ Am Soc Nephrol2010318 [Epub ahead of print].
   Web of Science ®Google Scholar
• SummersSASteinmetzOMLiMTh1 and Th17 cells induce proliferative glomerulonephritisJ Am Soc Nephrol200920122518252419820122
   PubMed Web of Science ®Google Scholar
• WeinblattMEKavanaughABurgos-VargasRTreatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trialArthritis Rheum200858113309331818975322
   PubMed Web of Science ®Google Scholar
• SmithJMcDaidJBhangalGTreatment with a spleen tyrosine kinase inhibitor reduces the severity of established antibody-mediated glomerulonephritisJ Am Soc Nephrol201021223123619959716
   PubMed Web of Science ®Google Scholar
• DaikelerTKotterIBocelli TyndallCHaematopoietic stem cell transplantation for vasculitis including Behcet’s disease and polychondritis: A retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literatureAnn Rheum Dis200766220220716950809
   PubMed Web of Science ®Google Scholar
• PallanLSavageCOHarperLANCA-associated vasculitis: From bench research to novel treatmentsNat Rev Nephrol20095527828619384329
   PubMed Web of Science ®Google Scholar
• MukhtyarCGuillevinLCidMCEULAR recommendations for the management of primary small and medium vessel vasculitisAnn Rheum Dis200968331031718413444
   PubMed Web of Science ®Google Scholar